Pazopanib ameliorates acute lung injuries via inhibition of MAP3K2 and MAP3K3
Yuan Q, Basit A, Liang W, Qu R, Luan Y, Ren C, Li A, Xu X, Liu X, Yang C, Kuo A, Pierce R, Zhang L, Turk B, Hu X, Li F, Cui W, Li R, Huang D, Mo L, Sessa WC, Lee PJ, Kluger Y, Su B, Tang W, He J, Wu D. Pazopanib ameliorates acute lung injuries via inhibition of MAP3K2 and MAP3K3. Science Translational Medicine 2021, 13 PMID: 33910977, PMCID: PMC8466683, DOI: 10.1126/scitranslmed.abc2499.Peer-Reviewed Original ResearchConceptsAcute lung injuryLung injuryMyeloid cellsLung transplantation recipientsMouse ALI modelPulmonary barrier functionTransplantation recipientsALI modelReactive oxygen species formationPharmacological interventionsPazopanibOxygen species formationVasculature integrityEpithelial cell survivalHigh mortalityMitogen-activated protein kinase kinase kinase 2Barrier functionGenetic inactivationInjuryCell survivalMortalityProtein kinase kinase kinase 2MAP3K3Kinase 2Manifestations